Skip to content

ABEONA THERAPEUTICS INC.: 10-K filed 2017-03-30

What ABEONA THERAPEUTICS INC. reported in its annual report filed 2017-03-30 (fiscal FY 2016): 27 published measures, 56 facts as tagged in accession 0001144204-17-017709.

This filing

Form
10-K (annual report)
Filed
2017-03-30
Fiscal period
fiscal FY 2016
Accession
0001144204-17-017709 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ABEONA THERAPEUTICS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-12-31111,058,000USD
At 2015-12-3180,055,000USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-12-3111,960,000USD
At 2015-12-3112,334,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-12-3199,098,000USD
At 2015-12-3167,721,000USD
At 2014-12-314,816,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-12-3169,142,000USD
At 2015-12-3140,138,000USD
At 2014-12-3111,520,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-01-01 to 2016-12-31-21,873,000USD366
2015-01-01 to 2015-12-31-14,526,000USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2016-01-01 to 2016-12-31519,000USD366
2015-01-01 to 2015-12-31308,000USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-12-31-332,473,000USD
At 2015-12-31-310,600,000USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2016-01-01 to 2016-12-3134,180,253shares366
2015-01-01 to 2015-12-3127,597,434shares365

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2016-01-01 to 2016-12-310USD366
2015-01-01 to 2015-12-310USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-12-31721,000USD
At 2015-12-31350,000USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-12-31-23,881,000USD366
2015-01-01 to 2015-12-31-18,546,000USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-12-3169,421,000USD
At 2015-12-3140,568,000USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-12-318,296,000USD
At 2015-12-311,477,000USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2016-12-313,694,000USD
At 2015-12-31875,000USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2016-12-3132,466,000USD
At 2015-12-3132,466,000USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2016-12-318,384,000USD
At 2015-12-316,609,000USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-01-01 to 2016-12-3110,655,000USD366
2015-01-01 to 2015-12-314,715,000USD365

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2016-12-31900,000USD
At 2015-12-31381,000USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2016-12-31179,000USD
At 2015-12-3131,000USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2016-12-31155,000USD
At 2015-12-31315,000USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2016-12-310USD
At 2015-12-310USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2016-01-01 to 2016-12-31-21,873,000USD366
2015-01-01 to 2015-12-31-14,526,000USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-01-01 to 2016-12-3113,290,000USD366
2015-01-01 to 2015-12-3114,320,000USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2016-01-01 to 2016-12-31825,000USD366
2015-01-01 to 2015-12-31551,000USD365

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2016-01-01 to 2016-12-31677,000USD366
2015-01-01 to 2015-12-31538,000USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2016-01-01 to 2016-12-312,008,000USD366
2015-01-01 to 2015-12-314,020,000USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-12-312,819,000USD366
2015-01-01 to 2015-12-31-1,174,000USD365

Inspect the source

Entity
ABEONA THERAPEUTICS INC. / CIK 0000318306
Captured
2026-09-19T14:56:42.310Z
SEC response SHA-256
636768f46653d2a6ef88c7a2f3600aa36414b265029032bf07e61c32ce5542a2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000318306.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))